A new tool for estimating liver cancer risk after a hepatitis C virus cure.
作者信息
Innes Hamish, Irving William L
机构信息
School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.
NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.
出版信息
Hepatobiliary Surg Nutr. 2020 Dec;9(6):791-793. doi: 10.21037/hbsn.2020.03.08.
Abstract
摘要
相似文献
1
A new tool for estimating liver cancer risk after a hepatitis C virus cure.一种用于评估丙型肝炎病毒治愈后肝癌风险的新工具。
Hepatobiliary Surg Nutr. 2020 Dec;9(6):791-793. doi: 10.21037/hbsn.2020.03.08.
2
Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study.在一项单臂机制性研究中，超短疗程、基于应答指导的索磷布韦和达卡他韦治疗丙型肝炎的疗效。
Elife. 2023 Jan 9;12:e81801. doi: 10.7554/eLife.81801.
3
Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis.慢性病毒性肝炎治愈前后肝脏髓系细胞图谱
J Hepatol. 2024 Feb;80(2):251-267. doi: 10.1016/j.jhep.2023.02.040. Epub 2023 Mar 25.
4
The Impact of Markers of HIV Infection on Change in Liver Stiffness in People With HIV and Hepatitis C Virus Co-infection After Treatment and Cure of Hepatitis C.HIV 感染标志物对丙型肝炎病毒合并感染患者丙型肝炎治愈后肝硬度变化的影响。
J Acquir Immune Defic Syndr. 2020 Dec 15;85(5):e81-e89. doi: 10.1097/QAI.0000000000002487.
5
A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B.一种用于预测慢性乙型肝炎功能性治愈后肝脏相关结局的机器学习模型。
J Hepatol. 2025 Feb;82(2):235-244. doi: 10.1016/j.jhep.2024.08.016. Epub 2024 Aug 31.
6
Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry.即使慢性丙型肝炎患者经抗病毒治疗后病毒得到清除，肝酶升高仍预示着发病率和死亡率：来自德国丙型肝炎注册研究的数据。
Hepatol Commun. 2022 Sep;6(9):2488-2495. doi: 10.1002/hep4.2015. Epub 2022 Jun 5.
7
'I'm not hep C free': afterlives of hepatitis C in the era of cure.“我不是丙型肝炎病毒（HCV）清除者”：治愈时代丙型肝炎的后生命。
Med Humanit. 2023 Dec 19;49(4):678-687. doi: 10.1136/medhum-2023-012653.
8
[Clinical cure of hepatitis B: consensus and controversy].[乙肝的临床治愈：共识与争议]
Zhonghua Gan Zang Bing Za Zhi. 2020 Aug 20;28(8):636-639. doi: 10.3760/cma.j.cn501113-20200722-00409.
9
Chronic hepatitis B: what should be the goal for new therapies?慢性乙型肝炎：新疗法的目标应该是什么？
Antiviral Res. 2013 Apr;98(1):27-34. doi: 10.1016/j.antiviral.2013.01.006. Epub 2013 Feb 4.
10
Risk of hepatocellular carcinoma after hepatitis C virus cure.丙型肝炎病毒治愈后肝细胞癌的风险。
World J Gastroenterol. 2022 Jan 7;28(1):96-107. doi: 10.3748/wjg.v28.i1.96.
引用本文的文献
1
Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma.病毒性肝炎相关肝细胞癌的危险因素与预防
Front Oncol. 2021 Sep 9;11:686962. doi: 10.3389/fonc.2021.686962. eCollection 2021.
本文引用的文献
1
Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.口服抗病毒药物治疗后，丙型肝炎相关代偿性晚期慢性肝病患者肝脏相关事件的无创预测。
J Hepatol. 2020 Mar;72(3):472-480. doi: 10.1016/j.jhep.2019.10.005. Epub 2019 Oct 17.
2
Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.在基线肝硬化或高 FIB-4 评分的患者中，HCV 清除后长达 10 年仍存在肝细胞癌风险增加。
Gastroenterology. 2019 Nov;157(5):1264-1278.e4. doi: 10.1053/j.gastro.2019.07.033. Epub 2019 Jul 26.
3
Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents.直接作用抗病毒药物治疗的 HCV 患者的肝细胞癌长期风险。
Hepatology. 2020 Jan;71(1):44-55. doi: 10.1002/hep.30823. Epub 2019 Aug 19.
4
Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.丙型肝炎抗病毒治疗后肝细胞癌风险预测模型的建立。
J Hepatol. 2018 Nov;69(5):1088-1098. doi: 10.1016/j.jhep.2018.07.024. Epub 2018 Aug 21.
5
Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?直接作用抗病毒药物治疗丙型肝炎病毒感染：100%治愈？
Liver Int. 2018 Feb;38 Suppl 1(Suppl 1):7-13. doi: 10.1111/liv.13673.
6
Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis.多伦多肝癌风险指数：一种经过验证的评分系统，用于预测肝硬化患者患肝癌的10年风险。
J Hepatol. 2017 Aug 24. doi: 10.1016/j.jhep.2017.07.033.
7
An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis.肝硬化患者肝细胞癌监测的利弊评估
Hepatology. 2017 Apr;65(4):1196-1205. doi: 10.1002/hep.28895. Epub 2016 Dec 19.
8
Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.1980 - 2015年全球、区域和国家249种死因的预期寿命、全死因死亡率和死因别死亡率：全球疾病负担研究2015的系统分析
Lancet. 2016 Oct 8;388(10053):1459-1544. doi: 10.1016/S0140-6736(16)31012-1.
9
Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy.丙型肝炎病毒相关肝硬化中纤维化和门静脉高压的消退以及无干扰素抗病毒治疗后的持续病毒学应答
J Viral Hepat. 2016 Dec;23(12):994-1002. doi: 10.1111/jvh.12578. Epub 2016 Aug 8.
10
Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.丙型肝炎病毒感染退伍军人持续病毒学应答后发生肝细胞癌的风险
Hepatology. 2016 Jul;64(1):130-7. doi: 10.1002/hep.28535. Epub 2016 Apr 19.
Zotero 插件